1. Glucosylceramide Synthase Protects Glioblastoma Cells Against Autophagic and Apoptotic Death Induced by Temozolomide and Paclitaxel
- Author
-
Laura Riboni, Paola Giussani, Manuela Caroli, F. De Zen, E. Riccitelli, L. Brioschi, R. Campanella, Sergio M. Gaini, Rosaria Bassi, V. Anelli, and Paola Viani
- Subjects
Cancer Research ,Ceramide ,Paclitaxel ,Cell Survival ,medicine.medical_treatment ,Antineoplastic Agents ,Apoptosis ,Ceramides ,Central Nervous System Neoplasms ,chemistry.chemical_compound ,Cell Line, Tumor ,Autophagy ,Temozolomide ,medicine ,Humans ,Cytotoxic T cell ,Cytotoxicity ,Antineoplastic Agents, Alkylating ,Cell Proliferation ,Chemotherapy ,General Medicine ,Antineoplastic Agents, Phytogenic ,Cell biology ,Dacarbazine ,Oncology ,chemistry ,Drug Resistance, Neoplasm ,Glucosyltransferases ,Cell culture ,Cancer research ,Glioblastoma ,medicine.drug - Abstract
Glioblastoma is a deadly cancer with intrinsic chemoresistance. Understanding this property will aid in therapy. Glucosylceramide synthase (GCS) is associated with resistance and poor outcome; little is known about glioblastomas. In glioblastoma cells, temozolomide and paclitaxel induce ceramide increase, which in turn promotes cytotoxicity. In drug-resistant cells, both drugs are unable to accumulate ceramide, increased expression and activity of GCS is present, and its inhibitors hinder resistance. Resistant cells exhibit cross-resistance, despite differing in marker expression, and cytotoxic mechanism. These findings suggest that GCS protects glioblastoma cells against autophagic and apoptotic death, and contributes to cell survival under chemotherapy.
- Published
- 2012